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Abstract
Background Prescribing, dispensing and administering pro re nata (PRN; as needed or necessary, as determined by an indi-
vidual) medicines to people with intermittent or short-term conditions is a potential area for medication errors and inappro-
priate prescribing and administration. In people with dementia, regular PRN medicines use can demonstrate good practice 
when appropriate or poor in situations where their use is not recommended. However, the frequency of PRN prescription and 
administration within long-term care settings (care homes) for people with dementia is largely unknown. A limited number 
of studies worldwide suggest variation between countries. Objective To describe the prescription and administration rates 
of PRN medicines for people with dementia in UK care homes. Setting Fifty UK care homes. Method Medication details 
were collected from review of residents’ medicines records within the care home for the previous month. Main outcome 
measure Prescription and administration of PRN medicines for the treatment of behaviours associated with neuropsychiatric 
symptoms and pain. Results The most commonly prescribed PRN medicines were analgesics (35.3%), although lower levels 
of PRN prescription were observed compared to recent studies. The percentage of residents receiving PRN administrations 
varied, with 20% for antipsychotics, 50% for benzodiazepines, 59% for analgesics, and 85.7% for nonbenzodiazepine hypnot-
ics being administered. Conclusion Further research is needed to understand the decision making in PRN prescription and 
administration within long-term care. The prescribing of potentially inappropriate medicines remains a problem in long-term 
care settings and pharmacists have a key role in reducing inappropriate polypharmacy by undertaking medication reviews 
that consider both regular and PRN medicines.
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Impact on practice
• There are inconsistencies in practice for people living 
with dementia and memory problems in care homes, and 
regular medication reviews are required.
• Non-pharmacological alternatives should be considered 
for the management of neuropsychological symptoms for 
people living with dementia and memory problems.
• Particular attention should be given to ensure appropriate 
antipsychotic prescription for people with dementia and 
memory problems in care homes. Antipsychotics should 
only be used where absolutely necessary, and only in the 
short term.
Introduction
Dementia affects approximately 47 million people world-
wide, and this is projected to rise [1]. Around 20–40% 
of people with dementia live in long-term care [2, 3]. 
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Multimorbidity (having more than one long term condition) 
[4] and thus polypharmacy (taking multiple medicines; often 
defined as ≥ 4 medicines [5]) is highly prevalent and con-
cerning in long-term care, with 91% of long-term care resi-
dents taking 5+ medicines [5]. A study conducted in Eng-
land suggested that risks of polypharmacy include multiple 
side effects, increased risk of preventable hospitalisations, 
impaired quality of life, increased likelihood of interactions 
between medicines [4] and higher risks of medication errors, 
which are common in this population [6, 7]. In addition, 
inappropriate (over or under) prescribing, is commonplace 
[8] with implications for health and well-being and associ-
ated cost burden to the healthcare system. On average, 50% 
(range 24–80%) of people living in long-term care receive at 
least one inappropriate medicine and up to 30% of residents 
with advanced dementia are prescribed medicines classi-
fied as ‘never appropriate’ for this population [9]. There-
fore, understanding the prescription and administration of 
medicines for residents in long-term care is a clinical and 
policy imperative.
PRN medicines in long‑term care
Prescribing, dispensing and administering pro re nata (PRN; 
as needed or necessary, as determined by an individual) 
medicines to people with intermittent or short-term condi-
tions is a potential area for medication errors and inappro-
priate prescribing/administration. PRN medicines are given 
when an individual requires them, rather than as a regular 
daily dose or at specific times e.g. during a medication round 
[10]. Long-term care residents with dementia who may have 
impaired communication rely on staff making accurate and 
timely judgements of need for administration of PRN medi-
cines. For example, those with impaired communication or 
who have difficulties taking medicines have been noted to 
receive less PRN medicines [11]. As a result, guidelines 
have been developed aimed at improving appropriate assess-
ment and administration of PRN medicines in long-term care 
settings [12, 13].
Alongside warranted variations in PRN administration 
between residents, unwarranted variations between long-
term care settings exist, suggesting PRN use may not be 
based on individual resident needs, but organisation level 
factors, such as staffing levels and care home size [11, 14] 
and staff confidence or knowledge to make judgments about 
the necessity for PRN medicine administration [15]. The 
absence of clear instructions for staff on how and when to 
administer medicines increases the likelihood of adverse 
events or errors [12]. Therefore, PRN medicines adminis-
tration may be a signal of underlying care culture and quality 
and a risk factor in poorer quality care settings.
In people with dementia, regular PRN medicines use 
can demonstrate good practice when appropriate (e.g. 
PRN administration of appropriate analgesics may indi-
cate effective assessment and management of acute or 
intermittent pain) or poor practice (e.g. PRN administra-
tion of antipsychotics may indicate use as a first rather 
than last resort for managing agitation). This is of con-
cern given the increased risks of these drugs for falls, 
stroke and death [16] and their recommendation for use 
only in the short term, if closely monitored and after all 
psychosocial approaches have been exhausted [17]. Fre-
quent administration of PRN medicines such as pain relief 
however, may indicate the need for a medication review 
as a PRN prescription may be inappropriate. For exam-
ple, antipsychotics should be limited to residents who are 
severely distressed or at risk of harming themselves or 
others, and where non-pharmacological interventions have 
failed. Whilst antipsychotics have proven modest efficacy, 
side effects can be disabling and they increase the risk 
of cognitive decline, stroke and death [18]. Likewise the 
use of certain non-benzodiazepine hypnotics known as Z 
drugs has been found to increase of bone fractures and 
death [19]. Therefore prescription and administration of 
medicines such as anti-psychotics, benzodiazepines, non-
benzodiazepines, hypnotics and analgesia to people with 
dementia are of particular interest as they present poten-
tial high risks for well-being, quality of life and safety if 
administered incorrectly or not according to need.
However, the frequency of PRN prescription and admin-
istration within long-term care settings (care homes) is 
largely unknown. A limited number of studies worldwide 
suggest variation between countries. PRN prescription rates 
in care homes range from 91% in the USA [20] and 75% 
in Germany [21] to just 31% in Norway [22]. Significant 
within-country variations also exist: three studies con-
ducted in Australian long-term care settings found overall 
PRN prescription rates of 94% [23], 84% [11] and 7% [24]. 
Other studies have examined PRN medicine prescribing on 
a specific drug type basis. For example, the frequency of 
antipsychotic PRN prescription was 24.5% in a Canadian 
study [25], 23% in an Australian study [26], and 37% [27] 
and 15% [28] in two German studies. Analgesic prescribing 
on a PRN basis ranges from 40% in Germany [29], 48% in 
the USA [30], and 72% in Norway [31]. Where reported, the 
most commonly prescribed PRN medicines are analgesics 
[20, 21, 23, 32, 33] or anxiolytics/hypnotics [24].
Administration levels also vary; one US study reported 
administration rates of 30% over 7 days, while two Austral-
ian studies reported rates of 54% [11] and 28% [23]. Indi-
vidual medication-type PRN administrations also varied: 
administrations of analgesia were 30% in the USA [20] but 
only 12% in Norway [31]. Antipsychotic PRN administra-
tion rates are generally low. A Canadian study reported only 
2.1 PRN administrations on average per resident per month, 
with most residents receiving no administrations [25]. In 
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an Australian study, 11% of residents received at least one 
administration in a month [26], whilst in Germany this figure 
was just 6% [28].
Within the existing literature, two studies were specifi-
cally conducted with people living with dementia [20, 24] 
and dementia prevalence within the remaining samples 
ranged from 54 to 98.5% [26, 31]. Where this was exam-
ined those with a PRN prescription were more likely to have 
dementia ([28], 61 vs 39% [34]). However, one study [33] 
found no difference in the likelihood of PRN prescription 
in residents with and without dementia. Therefore, little is 
known about the prescribing or administration of PRN medi-
cines to people living with dementia in UK care homes.
In the present study, we were interested in the clinically 
significant class of PRN medicines related to the manage-
ment of neuropsychiatric symptoms and pain, which if 
not managed can lead to neuropsychiatric symptoms [35]. 
Pain assessment and management for people with demen-
tia is frequently suboptimal [29]. Despite known risks, and 
evidence suggesting widespread prescription but variable 
degrees of administration of PRN medicines, there is very 
limited understanding of PRN medication use in care homes 
for people living with dementia [36].
Aim of the study
We aimed to provide the first reported data on the rates of 
prescription and administration of PRN medicines associ-
ated with neuropsychiatric symptoms and pain management 
for people living with dementia and memory problems in 
UK long-term care settings (care homes).
Ethics approval
Ethical approval for the DCM-EPIC trial was gained from 
the Yorkshire and the Humber Leeds Bradford NHS REC 
[reference number 13/YH/0016]. Consent from study par-
ticipants included permission to reanalyse data for research 
purposes. Ethical approval for this sub-study was granted 
by Leeds Beckett University Research Ethics Committee.
Method
Data analysed in this paper was collected as part of the 
DCM-EPIC trial, a UK randomised controlled trial in care 
homes. The trial aimed to establish the effectiveness of a 
person-centred intervention for the quality of life of people 
living with dementia or memory problems. Baseline data 
(collected from May 2014–December 2015) on prescribed 
and administered medication were analysed for this paper.
Participants
Participants were recruited from 50 care homes in the United 
Kingdom. Residents with dementia diagnoses or memory 
problems (i.e. without a confirmed dementia diagnosis) were 
eligible to participate. Residents formally admitted to an end 
of life care pathway or who only resided semi-permanently 
were ineligible.
Procedure
Care homes were selected by listing all potentially eligible 
care homes across the three recruitment areas (West York-
shire, Oxfordshire and South London) using publicly avail-
able data. They were then randomly ordered within post-
code area/boroughs and the first 10–12 listed care homes 
approached from one post-code/borough in each hub. This 
method rotated across each postcode/borough until suffi-
cient homes were recruited. Approach was initially made 
by post, followed by a researcher phone call. Eligibility was 
confirmed for any homes potentially interested in participa-
tion ahead of consent. Care homes were recruited randomly, 
stratified by postcode, size, and type. Homes subject to regu-
latory enforcement or who were deemed ‘inadequate’ by the 
UK quality regulator (the Care Quality Commission) were 
ineligible to participate.
Medication details were collected from residents’ medi-
cine administration records for the previous month, held 
within their care home. Prescription of medicines relevant 
to the management of neuropsychiatric symptoms associated 
with dementia, physical and psychological health problems 
(e.g. antipsychotic, benzodiazepine, mood stabiliser) and 
pain (analgesic) and frequency of administration of these if 
prescribed on a PRN basis, was recorded on a standardised 
form by researchers. Demographic data including comor-
bidities was collected from resident care records.
Additionally, information about symptoms of agitation 
was collected using the Cohen-Mansfield Agitation Inven-
tory (CMAI [37]), which measures 29 behaviours typically 
associated with agitation/aggression. Staff members iden-
tified the frequency of 29 behaviours during the previous 
2 weeks, rated on a seven-point Likert scale (1–7) ranging 
from “never” to “several times an hour”. This measure shows 
moderate concurrent validity with scores on the Neuropsy-
chiatric Inventory—Nursing Home version Agitation sub-
scale (r = .52 [38]).
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Statistical analysis
We calculated descriptive data (counts and means) by resi-
dent and care home. To explore our hypothesis that indi-
vidual care home approach to medicines use were related 
to rates of PRN administration, we calculated Pearson’s 
correlation coefficients using SPSS version 25.
Results
Demographic characteristics
A total of 728 participants were recruited from 50 care 
homes (31 residential or nursing home, 19 dementia care 
specialist home). Care homes provided care for an average of 
31.8 residents, with an average of 77.7% of residents having 
dementia (see Table 1 for participant demographics). Partici-
pants had, on average, two comorbidities alongside dementia 
(range 0–14). Selected comorbidities often associated with 
PRN prescriptions included depression (n = 117, 16.1%), 
anxiety (n = 57, 7.9%), psychosis (n = 40, 5.5%), sleep dis-
turbance (n = 13, 1.8%), and delirium (n = 5, .7%). Demo-
graphic data were missing for two participants who were not 
included in analyses, providing a total of 726 participants.
Medication use
The total number of regular medicines prescribed per resi-
dent ranged from 0 to 28 (mean = 8.68, SD = 4.14) with 0–3 
on a PRN basis (Mean = .4, SD = .60). Eight residents (.1%) 
were not prescribed any medicines. The total number of 
medication prescriptions was 6266, of these 5949 (95.0%) 
were regularly prescribed and 317 (5.0%) prescribed on a 
PRN basis. The prevalence of regularly and PRN prescribed 
medicines is shown in Table 2, stratified by gender, age and 
Table 1  Participant demographics
Characteristics
Age at registration (years) M (SD) 85.6 (7.64)
Gender
Female 536 (73.8%)
Male 190 (26.2%)
Length of stay in care home (years) M (SD) 2.3 (2.34)
Ethnicity
White British/European 702 (96.7%)
Other 24 (3.3%)
Funding type
Local authority 352 (48.5%)
Self-funded 289 (39.8%)
Local authority and self-funded 34 (4.7%)
Continuing healthcare 48 (6.6%)
Missing 3 (.4%)
Dementia severity (measured by functional assessment staging tool)
1–3 6 (1%)
4 95 (13.6%)
5 74 (10.6%)
6 380 (54.5%)
7 142 (20.4%)
Missing 29 (3.9%)
Table 2  Pro re nata (PRN) 
prescribing for residents 
in care homes stratified by 
demographic characteristics 
(N = 726)
All numbers provided as N (% of category) unless otherwise specified
No PRN medicine 1 PRN medicine 2 PRN medicines 3 PRN medicines
Age
< 70 21 (70) 7 (23) 2 (7) –
70–79 86 (64) 37 (28) 9 (7) 2 (1)
80–89 232 (67) 93 (27) 19 (5) 4 (1)
≥ 90 130 (61) 68 (32) 14 (7) 2 (< 1)
All 469 (65) 205 (28) 44 (6) 8 (1)
Gender
Female 332 (62) 182 (34) 20 (4) 2 (< 1)
Male 137 (72) 44 (23) 6 (3) 3 (2)
Regular prescriptions
M (SD) range 8.03 (4.11) 0–28 8.72 (3.92) 1–23 8.81 (3.69) 3–17 8.60 (5.08) 4–16
0–4 92 (69) 37 (29) 2 (1) 2 (1)
5–9 230 (66) 102 (30) 14 (4) 1 (< 1)
≥ 10 147 (60) 87 (35) 10 (4) 2 (1)
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regular medication prescription, in line with previous report-
ing [21, 22].
The most frequently prescribed PRN medication were 
analgesics with over a third of participants (35.3%) pre-
scribed them (see Table 3 for breakdown of type of medica-
tion prescribed). All other PRN prescriptions were at very 
low levels, ranging from .4% for mood stabilisers to 5.4% for 
benzodiazepines. The class/individual medicines prescribed 
and administered can be seen in Table 4.
Correlation analyses
Neither the total number of prescribed medicines (r = .03, 
p > .05), nor the number of PRN medicines administered 
(r = .14, p > .05) correlated with care home.
Level of agitation (as measured by the CMAI), was 
associated with total number of PRN prescriptions (r = .08, 
p < .05), but not total number of regular and PRN prescrip-
tions (r = − .06, p > .05).
Discussion
The current study presented the first evidence on PRN 
medication prescribing and administration within UK 
long-term care settings (care homes) for people with 
dementia. The most commonly prescribed PRN medicines 
were analgesics, in line with most recent evidence [21]. 
However, this may not be universally positive as many 
staff members lack the skills to perform adequate pain 
assessments, meaning residents do not always receive 
analgesic medicines when needed [30]. This is particu-
larly important as cognitive impairment is associated with 
decreased likelihood of receiving PRN analgesics [31]. In 
addition, continuing potentially inappropriate long-term 
PRN analgesics without review, for example nonsteroi-
dal anti-inflammatory drugs (NSAIDs), may mask or 
cause potentially harmful interactions or adverse effects 
[39, 40]. Regular and PRN NSAIDs can cause peptic 
ulcer disease, may increase thrombotic risk and impair 
renal function with the potential for Acute Kidney Injury. 
NSAIDs also interact with many commonly prescribed 
medicines, including antihypertensives, antithrombotics, 
lithium and Selective Serotonin Reuptake Inhibitors [41]. 
Unfortunately, we did not collect data on the underly-
ing reasons why medications were prescribed (see study 
Table 3  Prevalence of prescribed and administered regular and PRN medicines (N = 726)
Medication N residents (%) 
prescribed
N medicines 
prescribed
N (%) medicines adminis-
tered of prescribed
Number of administrations per resident of those 
administered at least once over a month [M (SD) 
range]
Antipsychotic
Regular 93 (12.8) 96 – –
PRN 10 (1.4) 10 2 (20) 4.14 (8.30) 0–22
Benzodiazepine
Regular 43 (6.0) 47 – –
PRN 38 (5.4) 39 19 (50) 18.62 (35.84) 0–137
Non-benzodiazepine hypnotic
Regular 40 (5.5) 40 – –
PRN 6 (1.0) 6 5 (85.7) 28.83 (47.30) 0–123
Antidepressant
Regular 268 (37.0) 299 – –
PRN 3 (.4) 3 3 (100) 31 (41.87) 2–79
Cognition enhancing medicines
Regular 171 (23.6) 177 – –
Anticonvulsants
Regular 35 (4.8) 40 – –
Mood stabilisers
Regular 3 (.4) 3 – –
Analgesic
Regular 356 (50.1) 468 – –
PRN 256 (35.3) 259 151 (58.3) 25.14 (36.43) 0–122
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limitations). We therefore cannot rule out the possibility 
that staff behaviours relating to PRN use for people with 
dementia increase exposure to potentially inappropriate 
medications with an unfavourable balance of benefits and 
harms, when compared to alternative treatment options. 
More research is needed to ascertain the degree to which a 
diagnosis of dementia modifies the probability of meeting 
STOPP (Screening Tool of Older Person’s Prescriptions) 
or Beers criteria or not benefiting from START (Screening 
Tool to Alert doctors to Right Treatment) criteria [39, 40].
Our data was collected after publication of guidance on 
antipsychotic medication prescribing for people with demen-
tia within the UK [12]. This suggested antipsychotic medi-
cation should be used as a last resort, and not longer than 
6 weeks at a time. Within our sample, 1.4% had a prescrip-
tion for an antipsychotic medication on a PRN basis and 
12.7% on a regular basis. However, we cannot know whether 
the levels observed are specific to our sample without draw-
ing comparisons to other care home samples within the UK. 
Only one study has considered both regular and PRN antip-
sychotic use, where Managers reported that 8% of residents 
had a regular and 4% of residents had a PRN antipsychotic 
prescription [42], however caution should be exercised in 
interpreting this self-reported data from managers. The 
study also did not report how frequently prescribed PRN 
medications were administered. As our data were cross-
sectional we do not know how long regular antipsychotic 
medicines had been prescribed. A low level of PRN antip-
sychotic prescriptions was reported in a recent Australian 
study [23], although their seven-day data collection period 
included only one administration on average, whereas within 
our sample, there were two administrations across 1 month. 
Table 4  Medicines prescribed by name and type
Medication Total 
medicines 
prescribed
Regular PRN
Antipsychotic 106 96 10
Amisulpride 6 5 1
Aripriprazole 5 5 –
Chloropromazine 1 1 –
Flupentixol 3 3 –
Haloperidol 4 4 3
Levomepromazine 2 – 2
Olanzapine 17 17 –
Prochlorperazine 2 1 1
Quetiapine 19 19 –
Risperidone 43 40 2
Benzodiazepine 86 47 39
Clonazepam 2 2 –
Diazepam 24 13 11
Lorazepam 46 19 27
Midazolam 1 1 –
Nitrazepam 4 4 –
Oxazepam 1 1 –
Temazepam 8 7 1
Non-benzodiazepine hypnotic 46 40 6
Chlormethiazole 1 – 1
Melatonin 1 1 –
Zopiclone 44 39 5
Antidepressant 302 299 3
Amitriptyline 18 18 –
Citalopram 88 88 –
Dosulepin 1 1 –
Duloxetine 2 2 –
Escitalopram 2 2 –
Fluoxetine 9 9 –
Lofepramine 3 3 –
Mirtazapine 80 80 –
Paroxetine 2 2 –
Sertraline 26 26 –
Trazodone 61 58 3
Venlafaxine 7 7 –
Cognition enhancing medicines 177 177 –
Donepezil 87 87 –
Galantamine 19 19 –
Memantine 55 55 –
Rivastigmine 16 16 –
Anticonvulsants 40 40 –
Carbamazepine 10 10 –
Gabapentin 2 2 –
Lamotrigine 1 1 –
Levetiracetam 7 7 –
Phenobarbital 3 3 –
Phenytoin 2 2 –
Table 4  (continued)
Medication Total 
medicines 
prescribed
Regular PRN
Pregabalin 1 1 –
Sodium valproate 12 12 –
Topiramate 1 1 –
Mood stablisers 3 3 –
Lithium 3 3 –
Analgesic 724 468 256
Aspirin 102 101 1
Buprenorphine 21 21 –
Co-codamol 55 34 21
Codeine 42 27 15
Ibuprofen 23 18 5
Morphine 13 6 7
Paracetamol 447 243 204
Tramadol 9 8 1
Other 12 10 2
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This may reflect recent increased understanding about the 
potential harms of antipsychotic administration for people 
living with dementia [23] or the presence of good practice 
guidelines for care homes to work with [12, 13]. Whilst we 
observed generally low levels of PRN prescriptions and 
administrations, it is not known whether this is in response 
to the guidelines, as no evidence exists for the prevalence 
of PRN prescriptions in the UK before their development.
PRN medication administration varied within the present 
study. For some categories, such as antipsychotics, only 2 
of 10 residents received an administration within the one-
month data collection period. Other categories, such as ben-
zodiazepines and non-benzodiazepine hypnotics, were far 
more common. For example, 50% of participants prescribed 
these on a PRN basis received at least one administration 
during the month. However, some residents received over 
100 administrations of benzodiazepines and non-benzodi-
azepine hypnotics within the data collection period. Such 
under and over exploitation of possibilities suggests inap-
propriate PRN prescriptions for some residents and should 
trigger the need for a medication review. For example, a 
regular dose may have been warranted. Additionally, this 
may indicate a trend of prescribing benzodiazepines and 
other sedating drugs in place of antipsychotics, given the 
drivers to reduce the prescription of the latter in people with 
dementia, which is of concern. In addition to antipsychotics 
and benzodiazepines, other medicines that were prescribed 
would be deemed potentially inappropriate, particularly in 
people with dementia. For example, tricyclic antidepres-
sants, paroxetine and fluoxetine [39, 40]. Future research 
should explore this as there are clear guidelines regarding 
the long-term use of benzodiazepines within this popula-
tion [43]. This is due to issues around dependency, toxicity, 
cognitive decline, falls and increased sensitivity towards side 
effects such as delirium [44, 45]. The needs of long-term 
care residents should be regularly reviewed to ensure only 
required medicines are prescribed and administered and that 
PRN prescriptions remain appropriate [6]. This is particu-
larly important for those with dementia, as individuals with 
more severe cognitive impairment were less likely to receive 
pain relief on a PRN basis [20, 31] possibly as they strug-
gle to communicate their symptoms [23], or expressions of 
pain through behaviours such as agitation are attributed as a 
symptom of dementia [46]. However, in our study, we found 
that there was a weak but significant relationship between 
number of PRN prescriptions and scores on an agitation 
measure. Further research is needed to understand this rela-
tionship and how well understood the needs of individuals 
experiencing agitation are.
Previous research suggests the main predictor of PRN 
medication is often the care home in which the resident lives 
[11]. We found the likelihood of being prescribed PRN med-
icines did not differ by care home. This could be because 
PRN prescriptions for some categories (i.e. antipsychotics) 
were too small to generate significant differences, rather than 
a lack of differences.
Our research implies that PRN use is lower than antici-
pated, but the current research base does not allow us to 
state, with confidence, that this is a genuine shift in expected 
prescription and administration. Future research should seek 
to collate the datasets from several large-scale clinical tri-
als that have recently been completed in the UK, to estab-
lish whether this pattern of lower prescribing is seen more 
widely, before establishing whether a general trend towards 
lower PRN prescriptions for people with dementia is being 
seen generally.
Strengths and limitations
This study presented the first examination of PRN medica-
tion prescription and administration within UK care homes 
for people with dementia. Whilst the data are cross-sectional, 
they provide an overview of current prescribing practices. 
Although, we do not know whether as dementia progresses, 
individuals are more likely to receive prescriptions for PRN 
medicines. Existing evidence suggests that as residents 
spend longer in care homes, their likelihood of receiving a 
PRN prescription increases [21]. Future work should seek to 
examine changes in prescriptions and administrations over 
time and their association with harms in care homes, such 
as falls and hospitalisations. Our data only included those 
falls resulting in hospitalisation. We are unlikely to have 
captured their true extent, and so analysing this data would 
have been inappropriate. Furthermore, whilst we have data 
on frequency of administrations, we do not have dosage or 
reason for prescription, which limited interpretation of the 
appropriateness of prescriptions. Heterogeneous data col-
lection and research questions mean drawing comparisons 
between our findings and those of similar existing studies 
may be inappropriate.
Conclusion
For the first time in the UK, this study presented the first 
evidence of the prescription and administration of PRN 
medicines for neuropsychiatric symptoms and pain man-
agement for people living with dementia. Generally, low 
levels of prescriptions and even lower levels of administra-
tions were observed for the management of neuropsychiatric 
symptoms. This could be viewed positively as non-phar-
macological treatments for dementia are being encouraged. 
However, the variation seen in PRN administrations suggests 
more research is needed to understand UK practices. The 
prescribing of potentially inappropriate medicines remains 
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a problem in long-term care and pharmacists have a key 
role in reducing inappropriate polypharmacy by undertak-
ing medication reviews that consider both regular and PRN 
medicines.
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